• Home
  • News

Sichenzia Ross Ference LLP Represents Sunshine Biopharma, Inc. in $8 Million Private Placement

sunshine biopharma

Press Release – New York, NY – March 15, 2022 – Sichenzia Ross Ference LLP today announced that it represented Sunshine Biopharma, Inc.,  a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs (NASDAQ: SBFM), in a $8.0 million private placement.  The offering included 2,301,353 shares of common stock together with common warrants to purchase up to 2,301,353 shares of common stock, and 1,302,251 pre-funded warrants, together with common warrants to purchase up to 1,302,251 shares of common stock.  Each share of common stock and accompanying common warrant were sold together at a combined offering price of $2.22, and each pre-funded warrant and accompanying common warrant were sold together at a combined offering price of $2.219.  The common warrants have an exercise price of $2.22 per share.  The gross proceeds to the Company from the offering were approximately $8.0 million.

The Sichenzia Ross Ference LLP team was led by partners Gregory Sichenzia, Jeff Cahlon and David Manno and associate Michael Blane.

Sichenzia Ross Ference Carmel LLP